Extracellular vesicles derived from mesenchymal stromal cells mediate endogenous cell growth and migration via the CXCL5 and CXCL6/CXCR2 axes and repair menisci.
CXCR2
Extracellular vesicles
Meniscus regeneration
Mesenchymal stromal cell
RNA sequencing
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
22 07 2021
22 07 2021
Historique:
received:
10
03
2021
accepted:
29
06
2021
entrez:
23
7
2021
pubmed:
24
7
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) are promising candidates for tissue regeneration therapy. However, the therapeutic efficacy of MSC-EVs for meniscus regeneration is uncertain, and the mechanisms underlying MSC-EV-mediated tissue regeneration have not been fully elucidated. The aims of this study were to evaluate the therapeutic efficacy of intra-articular MSC-EV injection in a meniscus defect model and elucidate the mechanism underlying MSC-EV-mediated tissue regeneration via combined bioinformatic analyses. MSC-EVs were isolated from human synovial MSC culture supernatants via ultrafiltration. To evaluate the meniscus regeneration ability, MSC-EVs were injected intra-articularly in the mouse meniscus defect model immediately after meniscus resection and weekly thereafter. After 1 and 3 weeks, their knees were excised for histological and immunohistochemical evaluations. To investigate the mechanisms through which MSC-EVs accelerate meniscus regeneration, cell growth, migration, and chondrogenesis assays were performed using treated and untreated chondrocytes and synovial MSCs with or without MSC-EVs. RNA sequencing assessed the gene expression profile of chondrocytes stimulated by MSC-EVs. Antagonists of the human chemokine CXCR2 receptor (SB265610) were used to determine the role of CXCR2 on chondrocyte cell growth and migration induced by MSC-EVs. In the meniscus defect model, MSC-EV injection accelerated meniscus regeneration and normalized the morphology and composition of the repaired tissue. MSC-EVs stimulated chondrocyte and synovial MSC cell growth and migration. RNA sequencing revealed that MSC-EVs induced 168 differentially expressed genes in the chondrocytes and significantly upregulated CXCL5 and CXCL6 in chondrocytes and synovial MSCs. Suppression of CXCL5 and CXCL6 and antagonism of the CXCR2 receptor binding CXCL5 and CXCL6 negated the influence of MSC-EVs on chondrocyte cell growth and migration. Intra-articular MSC-EV administration repaired meniscus defects and augmented chondrocyte and synovial MSC cell growth and migration. Comprehensive transcriptome/RNA sequencing data confirmed that MSC-EVs upregulated CXCL5 and CXCL6 in chondrocytes and mediated the cell growth and migration of these cells via the CXCR2 axis.
Sections du résumé
BACKGROUND
Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) are promising candidates for tissue regeneration therapy. However, the therapeutic efficacy of MSC-EVs for meniscus regeneration is uncertain, and the mechanisms underlying MSC-EV-mediated tissue regeneration have not been fully elucidated. The aims of this study were to evaluate the therapeutic efficacy of intra-articular MSC-EV injection in a meniscus defect model and elucidate the mechanism underlying MSC-EV-mediated tissue regeneration via combined bioinformatic analyses.
METHODS
MSC-EVs were isolated from human synovial MSC culture supernatants via ultrafiltration. To evaluate the meniscus regeneration ability, MSC-EVs were injected intra-articularly in the mouse meniscus defect model immediately after meniscus resection and weekly thereafter. After 1 and 3 weeks, their knees were excised for histological and immunohistochemical evaluations. To investigate the mechanisms through which MSC-EVs accelerate meniscus regeneration, cell growth, migration, and chondrogenesis assays were performed using treated and untreated chondrocytes and synovial MSCs with or without MSC-EVs. RNA sequencing assessed the gene expression profile of chondrocytes stimulated by MSC-EVs. Antagonists of the human chemokine CXCR2 receptor (SB265610) were used to determine the role of CXCR2 on chondrocyte cell growth and migration induced by MSC-EVs.
RESULTS
In the meniscus defect model, MSC-EV injection accelerated meniscus regeneration and normalized the morphology and composition of the repaired tissue. MSC-EVs stimulated chondrocyte and synovial MSC cell growth and migration. RNA sequencing revealed that MSC-EVs induced 168 differentially expressed genes in the chondrocytes and significantly upregulated CXCL5 and CXCL6 in chondrocytes and synovial MSCs. Suppression of CXCL5 and CXCL6 and antagonism of the CXCR2 receptor binding CXCL5 and CXCL6 negated the influence of MSC-EVs on chondrocyte cell growth and migration.
CONCLUSIONS
Intra-articular MSC-EV administration repaired meniscus defects and augmented chondrocyte and synovial MSC cell growth and migration. Comprehensive transcriptome/RNA sequencing data confirmed that MSC-EVs upregulated CXCL5 and CXCL6 in chondrocytes and mediated the cell growth and migration of these cells via the CXCR2 axis.
Identifiants
pubmed: 34294118
doi: 10.1186/s13287-021-02481-9
pii: 10.1186/s13287-021-02481-9
pmc: PMC8296733
doi:
Substances chimiques
Receptors, Interleukin-8B
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
414Informations de copyright
© 2021. The Author(s).
Références
Cell Physiol Biochem. 2018;48(1):361-370
pubmed: 30016780
Osteoarthritis Cartilage. 2017 Sep;25(9):1531-1540
pubmed: 28506841
Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):289-312
pubmed: 30703432
J Orthop Res. 2017 Sep;35(9):1958-1965
pubmed: 27805288
Cell Death Dis. 2019 Feb 25;10(3):188
pubmed: 30804325
J Bone Joint Surg Am. 2010 Jun;92(6):1398-408
pubmed: 20516315
Nat Genet. 2006 Dec;38(12):1424-9
pubmed: 17099713
Stem Cells Int. 2018 Jul 12;2018:5310471
pubmed: 30123286
Regen Ther. 2018 Jan 23;8:20-28
pubmed: 30271862
Cytotherapy. 2016 Jul;18(7):816-27
pubmed: 27260205
Biomaterials. 2019 Apr;200:35-47
pubmed: 30771585
Arthritis Rheum. 2003 Aug;48(8):2178-87
pubmed: 12905471
J Control Release. 2017 Oct 28;264:112-126
pubmed: 28837823
J Physiol Biochem. 2018 Nov;74(4):559-568
pubmed: 29560554
FASEB J. 2018 Apr;32(4):2197-2211
pubmed: 29229683
Mol Ther Nucleic Acids. 2020 Sep 16;22:1078-1091
pubmed: 33294294
Front Bioeng Biotechnol. 2020 Mar 03;8:146
pubmed: 32195233
Osteoarthritis Cartilage. 2018 Feb;26(2):195-201
pubmed: 29146386
Stem Cell Reports. 2016 Apr 12;6(4):466-473
pubmed: 27052313
Osteoarthritis Cartilage. 2017 Jan;25(1):76-84
pubmed: 27539889
Trends Biochem Sci. 2021 Aug;46(8):640-651
pubmed: 33610425
Ann Med Surg (Lond). 2017 Oct 05;24:3-7
pubmed: 29062478
Angiogenesis. 2011 Dec;14(4):443-55
pubmed: 21779896
Biomaterials. 2019 Jun;206:87-100
pubmed: 30927715
J Immunol. 2009 Sep 1;183(5):3425-32
pubmed: 19667085
Front Bioeng Biotechnol. 2020 Dec 14;8:603598
pubmed: 33425869
J Extracell Vesicles. 2020 Mar 09;9(1):1735249
pubmed: 32284824
J Orthop Translat. 2019 Dec 06;21:73-80
pubmed: 32099807
Genome Biol. 2014;15(12):550
pubmed: 25516281
Cell Mol Life Sci. 2021 Jan;78(1):79-91
pubmed: 32601714
Biochem Biophys Res Commun. 2020 Mar 5;523(2):465-472
pubmed: 31882120
Ann Rheum Dis. 2015 Dec;74(12):2207-15
pubmed: 25135253
Front Physiol. 2020 Sep 25;11:579892
pubmed: 33101061
J Cell Mol Med. 2018 Feb;22(2):728-737
pubmed: 29083099
Orthop Traumatol Surg Res. 2017 Dec;103(8S):S237-S244
pubmed: 28873348
J Anat. 1983 Jun;136(Pt 4):773-91
pubmed: 6688412
Stem Cell Res Ther. 2017 Mar 9;8(1):64
pubmed: 28279188
Stem Cell Res Ther. 2016 Aug 31;7(1):125
pubmed: 27581859
Cell Death Dis. 2018 Feb 14;9(2):229
pubmed: 29445104
EFORT Open Rev. 2018 May 21;3(5):260-268
pubmed: 29951265
Am J Sports Med. 2020 May;48(6):1406-1415
pubmed: 32105507
Stem Cell Res Ther. 2020 Jun 17;11(1):239
pubmed: 32552749
J Immunol. 2000 Nov 1;165(9):5269-77
pubmed: 11046061
Stem Cell Res Ther. 2018 Mar 9;9(1):63
pubmed: 29523213
World J Stem Cells. 2021 Jan 26;13(1):49-63
pubmed: 33584979
Knee Surg Sports Traumatol Arthrosc. 2019 Feb;27(2):341-342
pubmed: 30535548
Biochem Biophys Res Commun. 2013 Jun 14;435(4):603-9
pubmed: 23685144
J Bone Joint Surg Am. 2016 Nov 2;98(21):1829-1836
pubmed: 27807116
Stem Cells. 2015 Jun;33(6):1927-38
pubmed: 25993981
Front Cell Dev Biol. 2020 Dec 10;8:593386
pubmed: 33363147
Cancer Res. 2010 Feb 15;70(4):1668-78
pubmed: 20124479
Ann Biomed Eng. 2015 Mar;43(3):529-42
pubmed: 25650096
Biochim Biophys Acta. 2001 May 28;1539(1-2):122-30
pubmed: 11389974
Curr Opin Cell Biol. 2013 Apr;25(2):233-40
pubmed: 23312066
Arthritis Rheumatol. 2019 Jul;71(7):1089-1100
pubmed: 30592385
World J Stem Cells. 2012 May 26;4(5):35-43
pubmed: 22993660